PATENT CLAIM ANALYSIS

Application Number: 16223009
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "131100"]

Abstract:
Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.

Claim (Index 1):
A monoclonal antibody, or an antigen binding fragment thereof, which:\n a. binds to human CD47; b. blocks SIRP\u03b1 binding to human CD47; c. increases phagocytosis of human tumor cells; d. induces death of human tumor cells; and\n wherein said monoclonal antibody, or an antigen binding fragment thereof, binds normal cells with an apparent K d  of at least 8-fold greater compared to binding to tumor cells.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 98.0
- Lexical Diversity: 1.47826
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15820054', '15473206', '15712010', '15711971', '14700105']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7986550710086908
- 35 USC 102 Novelty (BERT): 0.628858537332012
- Combined Prediction Score: 0.781675417641023
- Mean Citation Score: 504.45688200000006
- Max Citation Score: 732.706
- Similarity Product: 513.8156848315001

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test